Table of contents
August 2008 Vol 8 No 8
From the editors
p565 | doi:10.1038/nrc2457
Research Highlights
Angiogenesis: A less bitter pill | PDF (221 KB)
p567 | doi:10.1038/nrc2463
Leukaemia: Mixed up | PDF (256 KB)
p568 | doi:10.1038/nrc2445
Tumorigenesis: PUMA strikes again | PDF (228 KB)
p568 | doi:10.1038/nrc2449
In the news
Education, education, education | PDF (69 KB)
p568 | doi:10.1038/nrc2455
Angiogenesis: Survival of the infected | PDF (216 KB)
p569 | doi:10.1038/nrc2452
Therapeutics: Unravelling lethality | PDF (240 KB)
p570 | doi:10.1038/nrc2451
Angiogenesis: Mini mediator of metastasis suppression | PDF (142 KB)
p570 | doi:10.1038/nrc2453
Metastasis: Delivering help | PDF (221 KB)
p572 | doi:10.1038/nrc2447
Angiogenesis: TGF
makes a new friend | PDF
(403 KB)
p572 | doi:10.1038/nrc2448
Angiogenesis: Turning it down a Notch | PDF (258 KB)
p572 | doi:10.1038/nrc2450
Trial Watch
Targeting thyroid angiogenesis | PDF (78 KB)
p573 | doi:10.1038/nrc2456
In brief
Angiogenesis | Nanotechnology | Biomarkers | Senescence | PDF (87 KB)
p574 | doi:10.1038/nrc2454
Foreword
Focus on: Targeting Angiogenesis
Reviews
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis & Daniel J. Hicklin
p579 | doi:10.1038/nrc2403
The therapeutic benefit associated with VEGF-targeted therapy is complex, and probably involves multiple mechanisms, several of which are covered in this Review. Understanding these mechanisms more fully should lead to future advances in the use of these agents in the clinic.
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers & Douglas Hanahan
p592 | doi:10.1038/nrc2442
In both preclinical and clinical settings, the benefits of angiogenesis inhibitors targeting the vascular endothelial growth factor signalling pathways are at best transitory and followed by restoration of tumour growth and progression. Emerging data support a proposition that two modes of unconventional resistance underlie such results.
Integrins in angiogenesis and lymphangiogenesis
Christie J. Avraamides, Barbara Garmy-Susini & Judith A. Varner
p604 | doi:10.1038/nrc2353
Angiogenesis and lymphangiogenesis are regulated by integrins, which are cell surface receptors whose ligands are extracellular matrix proteins and immunoglobulin superfamily molecules. Here, the evidence implicating integrins as regulators of angiogenesis and lymphangiogenesis and the current state of therapeutic strategies to target them are discussed.
The role of myeloid cells in the promotion of tumour angiogenesis
Craig Murdoch, Munitta Muthana, Seth B. Coffelt & Claire E. Lewis
p618 | doi:10.1038/nrc2444
Bone marrow-derived myeloid cells, such as macrophages and mast cells, have an important role in regulating the formation and maintenance of blood vessels in tumours. How do these cells contribute to this process?
The semaphorins: versatile regulators of tumour progression and tumour angiogenesis
Gera Neufeld & Ofra Kessler
p632 | doi:10.1038/nrc2404
The semaphorins and their receptors, the neuropilins and the plexins, originally characterized as proteins involved in the guidance of axons, can either promote or inhibit tumour progression. This Review documents their effects on tumour angiogenesis, as well as on metastasis and cell survival.
Perspective
Timeline
The scientific contributions of M. Judah Folkman to cancer research
Bruce R. Zetter
p647 | doi:10.1038/nrc2458
M. Judah Folkman is regarded by many as the father of research into the therapeutic targeting of angiogenesis. For cancer research, what were his most notable achievements?
Corrigendum: Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Mark W. Dewhirst, Yiting Cao & Benjamin Moeller
p654 | doi:10.1038/nrc2438
